Depomed Inc (DEPO) Files Form 4 Insider Selling : Thadd M Vargas Sells 15,000 Shares

Depomed Inc (DEPO): Thadd M Vargas , Senior VP, BD of Depomed Inc sold 15,000 shares on May 10, 2016. The Insider selling transaction was reported by the company on May 10, 2016 to the Securities and Exchange Commission. The shares were sold at $17.64 per share for a total value of $264,600.00 , the company said in a SEC Form 4 Filing.

Other Insider transactions have been reported by the company according to SEC Form 4, on May 9, 2016, August J Moretti (Chief Financial Officer & SVP) sold 5,000 shares at $18.00 per share price.On Mar 11, 2016, Thadd M Vargas (Senior VP, BD) sold 23,000 shares at $16.00 per share price.

Shares of Depomed Inc (DEPO) ended Friday, May 6, 2016 session in red amid volatile trading. The shares closed down -0.64 points or -3.96% at $15.51 with 24,03,509 shares getting traded. Post opening the session at $15.35, the shares hit an intraday low of $15.11 and an intraday high of $16.09 and the price vacillated in this range throughout the day. The company has a market cap of $945 M and the number of outstanding shares has been calculated to be 6,09,03,857 shares. The 52-week high of Depomed Inc is $33.74 and the 52-week low is $12.25.

Depomed Inc Money Flow Index Chart

Company has been under the radar of several Street Analysts.Depomed Inc is Upgraded by Mizuho to Buy and the brokerage firm has set the Price Target at $19. Earlier the firm had a rating of Neutral on the company shares. The Rating was issued on May 9, 2016.Depomed Inc is Reiterated by Mizuho to Neutral and the brokerage firm has raised the Price Target to $ 18 from a previous price target of $14 .The Rating was issued on Apr 11, 2016.Depomed Inc is Initiated by Northland Capital to Outperform. The Rating was issued on Mar 24, 2016.Depomed Inc is Reiterated by Mizuho to Neutral while Lowering the Price Target of the company shares to $ 14 from a previous price target of $16 . The Rating was issued on Mar 24, 2016.Depomed Inc is Initiated by Leerink Partners to Outperform and the brokerage firm has set the Price Target at $21. The Rating was issued on Mar 10, 2016.

Depomed Inc. is a specialty pharmaceutical company focused on pain and other central nervous system (CNS) conditions. The Company’s products include Gralise (gabapentin) CAMBIA (diclofenac potassium for oral solution) Zipsor (diclofenac potassium) and Lazanda (fentanyl). Gralise is a once-daily product for the management of postherpetic neuralgia (PHN). CAMBIA is a non-steroidal anti-inflammatory drug (NSAID) for the acute treatment of migraine attacks. Zipsor a liquid filled capsule is a NSAID for the treatment of mild to moderate acute pain. Lazanda nasal spray is used for the management of break through pain in cancer patients 18 years of age and older who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain. It also has a portfolio of license agreements based on its Acuform gastroretentive drug delivery technology. The Company’s product DM-1992 has completed a Phase II trial for Parkinson’s disease.

Leave a Reply

Depomed Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Depomed Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.